Aptose Biosciences (APTO) Is At $1.55 Formed Wedge; Shorts at Zogenix (ZGNX) Lowered By 6.74%

September 11, 2017 - By Ellis Scott

Zogenix Incorporated (NASDAQ:ZGNX) had a decrease of 6.74% in short interest. ZGNX’s SI was 3.50M shares in September as released by FINRA. Its down 6.74% from 3.75 million shares previously. With 196,200 avg volume, 18 days are for Zogenix Incorporated (NASDAQ:ZGNX)’s short sellers to cover ZGNX’s short positions. The SI to Zogenix Incorporated’s float is 24.7%. About 254,738 shares traded. Zogenix, Inc. (NASDAQ:ZGNX) has risen 52.57% since September 11, 2016 and is uptrending. It has outperformed by 35.87% the S&P500.

Aptose Biosciences Inc (APTO) formed wedge up with $1.69 target or 9.00% above today’s $1.55 share price. Aptose Biosciences Inc (APTO) has $37.27 million valuation. About 46,803 shares traded. Aptose Biosciences Inc (NASDAQ:APTO) has declined 60.81% since September 11, 2016 and is downtrending. It has underperformed by 77.51% the S&P500.

Among 5 analysts covering Zogenix (NASDAQ:ZGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Zogenix had 10 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, June 26. Zacks upgraded the shares of ZGNX in report on Thursday, August 6 to “Sell” rating. The firm earned “Outperform” rating on Tuesday, August 11 by Leerink Swann. The firm has “Buy” rating given on Thursday, September 17 by Brean Capital. The stock has “Buy” rating by Brean Capital on Friday, August 14. The stock has “Hold” rating by Zacks on Saturday, August 15.

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system therapies that address specific clinical needs for people living with orphan and other CNS disorders. The company has market cap of $377.58 million. The Company’s primary area of therapeutic focus is epilepsy and related seizure disorders. It currently has negative earnings. The Company’s lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Among 4 analysts covering Aptose Biosciences (NASDAQ:APTO), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Aptose Biosciences has $20 highest and $100 lowest target. $6.85’s average target is 341.94% above currents $1.55 stock price. Aptose Biosciences had 11 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Wednesday, August 9 with “Hold”. The stock of Aptose Biosciences Inc (NASDAQ:APTO) earned “Buy” rating by Roth Capital on Monday, June 13. The firm has “Buy” rating given on Thursday, September 7 by H.C. Wainwright. The stock of Aptose Biosciences Inc (NASDAQ:APTO) has “Hold” rating given on Friday, August 7 by Zacks. The rating was downgraded by Roth Capital on Friday, November 20 to “Neutral”. As per Wednesday, November 11, the company rating was maintained by RBC Capital Markets. TH Capital downgraded the shares of APTO in report on Friday, November 20 to “Neutral” rating. As per Thursday, June 8, the company rating was initiated by H.C. Wainwright. On Wednesday, November 16 the stock rating was maintained by RBC Capital Markets with “Outperform”.